Kyle Hvidsten, MPH
Articles
October 1st 2009
Effects of a Medicaid Prior Authorization Policy for Pregabalin
Jay M. Margolis, PharmD Stephen S. Johnston, MA Bong-Chul Chu, PhD Eberechukwu Onukwugha, PhD Kyle Hvidsten, MPH Jose Alvir, DrPH Joseph G. Rossi, PharmD C. Daniel Mullins, PhD
State Medicaid programs’ pregabalin prior authorization accomplished the objective of lower pregabalin utilization; the unintended effects were increased opioid use and increased disease-related healthcare costs.
Latest Updated Articles
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
